Literature DB >> 6712200

Comparative in vitro activities of cefpiramide and apalcillin against anaerobic bacteria.

H Wexler, W T Carter, B Harris, S M Finegold.   

Abstract

The in vitro activities of two new antimicrobial agents, apalcillin and cefpiramide (SM-1652), were evaluated against 324 strains of anaerobic bacteria. Apalcillin (a penicillin derivative) and cefpiramide (a semisynthetic cephalosporin) were compared with piperacillin, moxalactam, and cefoxitin. Organisms studied included the Bacteroides fragilis group, other Bacteroides species, fusobacteria, clostridia, nonsporeforming gram-positive rods, and anaerobic cocci. Piperacillin was found to be the most active overall, inhibiting 96% of the strains tested at its achievable level in serum (128 micrograms/ml). Apalcillin was comparable in activity to piperacillin, inhibiting 93% of anaerobes tested at this concentration. The other antibiotics inhibited ca. 80% of the strains at 32 micrograms/ml. In terms of activities against particular species, apalcillin was active against 75% of B. fragilis group strains and 97 to 100% of all other anaerobes. Cefpiramide inhibited 37% of B. fragilis group strains at 32 micrograms/ml and 68% at 64 micrograms/ml (a level that may be achievable with this drug). Cefpiramide inhibited 92% of all other anaerobes at 32 micrograms/ml and 95% at 64 micrograms/ml. The clostridia other than Clostridium perfringens were the most resistant (84% inhibited at 32 micrograms/ml and 95% inhibited at 64 micrograms/ml).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6712200      PMCID: PMC185465          DOI: 10.1128/AAC.25.2.162

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Susceptibility of anaerobes to cefoxitin and other cephalosporins.

Authors:  F P Tally; N V Jacobus; J G Bartlett; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1975-02       Impact factor: 5.191

2.  Antimicrobial therapy of anaerobic infections: a status report.

Authors:  S M Finegold
Journal:  Hosp Pract       Date:  1979-10

3.  Antibiotic disc susceptibility tests for rapid presumptive identification of Gram-negative anaerobic bacilli.

Authors:  V L Sutter; S M Finegold
Journal:  Appl Microbiol       Date:  1971-01

4.  The activity of five cephalosporins against Bacteroides fragilis.

Authors:  R W Ryan; I Kwasnik; R C Tilton
Journal:  Ann Clin Lab Sci       Date:  1982 Jan-Feb       Impact factor: 1.256

5.  Piperacillin against clinical isolates: antimicrobial profile and clinical role.

Authors:  T A McAllister
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

6.  Susceptibility of Anaerobic bacteria to carbenicillin, cefoxitin, and related drugs.

Authors:  V L Sutter; S M Finegold
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

7.  Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria.

Authors:  M V Borobio; J Aznar; R Jimenez; F Garcia; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

8.  Susceptibilities of anaerobic bacteria to cefoperazone and other antibiotics.

Authors:  D Kaye; W Kobasa; K Kaye
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

9.  Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.

Authors:  R N Jones; P C Fuchs; H M Sommers; T L Gavan; A L Barry; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

Review 10.  Gram-negative anaerobic bacilli: their role in infection and patterns of susceptibility to antimicrobial agents. I. Little-known Bacteroides species.

Authors:  B D Kirby; W L George; V L Sutter; D M Citron; S M Finegold
Journal:  Rev Infect Dis       Date:  1980 Nov-Dec
View more
  5 in total

1.  Cell-wall-defective variants of Fusobacterium.

Authors:  C C Johnson; H M Wexler; S Becker; M Garcia; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

2.  Interpretive standards and quality control guidelines for cefpiramide disk susceptibility tests.

Authors:  A L Barry; T L Gavan; C Thornsberry; R N Jones
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

3.  Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins.

Authors:  N J Khan; J A Bihl; R F Schell; J L LeFrock; S J Weber
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

4.  In vitro activity of cefbuperazone against anaerobic bacteria.

Authors:  H Wexler; W T Carter; B H Harris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

5.  Comparative in vitro activity of cefpiramide, a new parenteral cephalosporin.

Authors:  C Quentin; P Noury; M Titonel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.